

PRESS RELEASE

August 17, 2005

Popcorn Marketing's **"Blue Agave Nectar"**

Passes Low Glycemic Protocol

Glycemic Solutions, the Official Clinical Testing Facility for the Glycemic Research Institute in Washington, D.C., announced today that independent, In Vivo clinical studies on Popcorn Marketing's *Blue Agave Nectar* have been completed, and that the product is Low Glycemic.

Human clinical trials on *Blue Agave Nectar* showed that the product is Low Glycemic in diabetics. Further, the product did not trigger Adipose tissue fat-storage in humans. This research shows that *Blue Agave Nectar* (at 1, 2 and 3 servings) does not trigger fat-storage in fat cells, and does not elevate blood glucose or insulin levels, which leads to obesity, insulin resistance, and diabetes.

Researchers noted that not all Agave products have been clinically proven to be low glycemic, as the manufacturing process and ratios of ingredients varies, and is not standardized.

Glycemic Solutions conducts ongoing University clinical studies in humans (In-Vivo) to determine the glycemic index, glycemic load, diabetic, and fat-storing properties of foods, providing independent clinical studies for the food and nutrition industries worldwide.

For the past 20 years, the Glycemic Research Institute has been the industry leader in glycemic research, receiving the first glycemic Patent, and Federal Certification ever awarded. Determining how humans metabolize foods allows scientists to gain insights as to the varying effects different foods have on human metabolism.

www.GlycemicIndexTesting.com